In fact, several studies have indicated that the level of nuclear expression of YB-1 is predictive of drug resistance and patient outcome in breast tumors, ovarian cancers, and synovial sarcomas [5,7,9-11]. Here, YBX1 is linked to ovarian carcinoma.